Cancer Medicine, Год журнала: 2025, Номер 14(6)

Опубликована: Март 1, 2025

ABSTRACT Background Chronic gut inflammation and dysbiosis contribute significantly to colorectal cancer (CRC) development. Shaoyao decoction (SYD) is a well‐established Chinese medicine prescription. Besides ameliorating CRC via anti‐inflammatory effects, SYD modulates microbiota (GM) improve inflammatory responses in ulcerative colitis (UC). However, whether how suppresses by regulating GM remains largely unknown. Methods SD rats were orally administered for 7 days obtain medicated serum. We utilized liquid chromatography–mass spectrometry (LC–MS) analysis, GeneCards, DisGeNET, SwissTargetPrediction databases analyze blank SYD‐medicated rat serum, comparing the findings with those of aqueous extract previous studies identify circulating compounds/components predictable target genes. Using network pharmacology, potential active compounds corresponding hub genes associated modulating suppress selected molecular docking. In vivo experiments, transplantation tumor model was established BALB/c mice using CT26 cells, gavage 14 days. To investigate mechanism SYD‐regulated against CRC, HE IHC staining, Western blotting, 16S rRNA sequencing employed. Results LC–MS identified 26 computationally predicted Network pharmacology prioritized 13 targeting 8 inflammation/immunity‐related (IL‐17/TNF pathways), validated dose‐dependently suppressed growth ( p < 0.05, medium/high doses), as confirmed staining analysis Ki‐67. Notably, potentially delayed liver metastasis alleviated hepatic injury tumor‐bearing mice. blotting demonstrated SYD's inhibition IL‐17/TNF/NF‐κB axis, aligning computational predictions. revealed SYD‐enriched Akkermansia structural shifts, mechanistically linking remodeling anti‐tumor efficacy. Conclusions combats dual modulation signaling ecosystems (e.g., enrichment). This microbiota‐immune crosstalk positions adjunct conventional therapies, particularly patients dysbiosis.

Язык: Английский